DIPARTIMENT TAS-SAĦĦA DEPARTMENT OF HEALTH
MALTA

L-Uffiċċju tal-Uffiċjal Mediku Ewlieni *Office of the Chief Medical Officer*

DH CIRCULAR No. 145/2012
DH. 2219/2012

22nd May 2012

Attention All: Doctors
Pharmacists
Pharmacy Technicians
Nurses

Re: Maraviroc 300mg Tablets

Maraviroc 300mg tablets have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

Maraviroc is a CCR5 inhibitor which selectively binds to the human cytokine receptor CCR5, preventing CCR5-tropic HIV-1 from entering cells.

In combination with other antiretroviral medicinal products, it is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.

Before taking maraviroc it has to be confirmed that only CCR5-tropic HIV-1 is detectable (i.e. CXCR4 or dual/mixed tropic virus not detected) using an adequately validated and sensitive detection method on a newly drawn blood sample.

In adults the recommended dose of Maraviroc is 300mg twice daily depending on interactions with co-administered antiretroviral therapy and other medicinal products. Maraviroc can be taken with or without food.

Consultant Infectious Diseases Physicians can prescribe maraviroc 300mg for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable exhibiting resistance to standard regime.

Maraviroc 300mg tablets are protocol-regulated with protocol number 121 (attached). Patients should be carefully reviewed. Candidates for treatment need to be chosen through the established committee made up of Consultant Infectious Diseases Physicians.

Maraviroc 300mg tablets have been procured through the Central Procurement and Supplies Unit and are now available for use as per protocol.

Dr. Natasha Azzopardi Muscat
Chief Medical Officer

"PALAZZO CASTELLANIA" 15, MERCHANTS STREET, VALLETTA, VLT 03
Tel. Nos. +00356 21224071/ 2299 2232 **Fax no. +00356 2299 2663**
e-mail: cmo.mhec@gov.mt

121

Maraviroc 300mg Tablets

Prescriber Criteria: Consultant Infectious Diseases Physician

Out-patient and In-patient use:

1. HIV/AIDS and Related Diseases

For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable exhibiting resistance to standard regime.

Patients should be carefully reviewed. Candidates for treatment need to be chosen through the established committee made up of Consultant Infectious Diseases Physicians.

Duration of Approval:
1 year